Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness

NCT ID: NCT00505323

Last Updated: 2014-07-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dystonia is a neurological movement disorder in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures. This disease is very heterogeneous and can have many causes. Current treatments (drugs, pallidal stimulation) improve primary generalized dystonias; however they are ineffective for focal dystonias following brain damage.

Cortex stimulation is a present and effective technique used in the treatment of chronic pain and could represent an interesting strategy to treat focal dystonias. This is the aim of the present study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pilot study included 6 centres (Clermont-Ferrand, Bordeaux, Paris, Créteil, Lyon and Grenoble)

Study progress :

* 3 months to 1 month before chirurgical intervention : selection of patient that could be included in the protocol.
* 15 days to 8 days before chirurgical intervention : inclusion visit.
* Operating phase : under anaesthesia, implantation of the neurostimulator and its components, and adjustment of stimulation parameters.
* 1 month after chirurgical intervention : checking that all is fine (detection of undesirable events)
* 2 months to 5 months after chirurgical intervention: randomization (double blind): the stimulator is put on position On or OFF
* 5 months after chirurgical intervention : Stimulators of all patients are stopped for one month whatever the group they belong.
* 6 months to 9 months after chirurgical intervention: Stimulatiors are put on position On or OFF (cross over with the first period).
* 9 months to 13 months after chirurgical intervention: Stimulators of all patients are started for four months whatever the group they belong.
* 13 months after chirurgical intervention : study end

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focal Dystonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation of neurostimulators and their auxiliary components

Implantation neurostimulators and their auxiliary components :

Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age : \>18 years and \< 65 years
* Evolution time of dystonia \> 1 year
* Clinical stability of dystonia = 1 year
* Secondary dystonia due to a focal lesion (vascular or anoxic) of central grey nuclei
* Inefficiency of others treatments (anticholinergic, benzodiazepine, neuroleptique, botulinum toxin, etc.)
* Stability of treatment \>3 months
* Agreement of patients
* Affiliation to social security

Exclusion Criteria

* Significant heart vascular disease; significant respiratory, metabolic, renal or hepatic diseases
* Significant clinical and biological anomalies
* Disease or treatment in favour in bleeding
* Sever cognitive disorders
* Psychiatric evolutionary pathology
* Counter-indication during inclusion examination
* Chirurgical counter-indication
* Pregnant women ou women who nurse
* Person who participate to an other study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Franck DURIF, Pr

Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRC N 2007 DURIF

Identifier Type: -

Identifier Source: secondary_id

2007-A00100-53

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation Surgery for Focal Hand Dystonia
NCT02911103 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
Neuroimaging of Dystonia
NCT02046447 COMPLETED
Surgery of Dystonia
NCT07140302 NOT_YET_RECRUITING NA
Lesioning Procedures for Movement Disorders
NCT06352268 NOT_YET_RECRUITING